BME
Get informed when a big investor buys or sells
+ FollowOvervalued by 97.2% based on the discounted cash flow analysis.
| Market cap | $560.13 Million |
|---|---|
| Enterprise Value | $560.82 Million |
| Dividend Yield | $3.15 (7.26%) |
| Earnings per Share | $5.92 |
| Beta | 0.6 |
| Outstanding Shares | 12,924,103 |
| P/E Ratio | 5.38 |
|---|---|
| PEG | -0.71 |
| Price to Sales | 6.19 |
| Price to Book Ratio | 0.99 |
| Enterprise Value to Revenue | 5.96 |
| Enterprise Value to EBIT | 6.79 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 19.88%▼ 0.56% |
|---|---|
| Total Invested | $111.05M▲ 9.13% |
| Investors Holding | 81▲ 3.00% |
No data
BlackRock Health Sciences Trust’s (BME) (the 'Trust') investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment ob...